Subcutaneous Leqembi approved for initiation; long-term stability with treatment indicated

The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according to a press release from the administration. Previously, patients had to begin treatment with an intravenous dose. Researchers conducting a real-world study, presented at the Alzheimer’s Association International Conference, found that most patients remained stable over an

Raccontata damorningstar.comeconomictimes.indiatimes.commedpagetoday.comhealio.com